GE HealthCare and Novo Nordisk to Collaborate to Advance Novel Non-invasive Treatment for Type 2 Diabetes and Obesity with Ultrasound
Published in Noninvasive.
Personalized peripheral focused ultrasound therapy has potential as non-invasive, non-pharmacological alternative for chronic disease management
Encouraging pre-clinical and early clinical data indicate potential use for people with type 2 diabetes
Collaboration pairs GE HealthCare expertise in ultrasound technology with Novo Nordisk long-term experience in metabolic disease treatment and management to develop solution to improve patient care
GE HealthCare (Nasdaq: GEHC) today announced a collaboration with Novo Nordisk to further advance the clinical and product development of peripheral focused ultrasound (PFUS). This is a novel technology that has potential to specifically regulate metabolic function in the body using ultrasound that may support the treatment of chronic diseases such as type 2 diabetes and obesity.
PFUS is a non-invasive type of bioelectronic medicine that uses ultrasound to activate the nervous system to stimulate a response that may be able to treat disease. Pre-clinical proof of concept and initial early-stage clinical research suggests that it may impact glucose metabolism in people with diabetes via personalized ultrasound stimulation of nerve pathways. If validated with further clinical evidence, PFUS could represent a non-pharmacologic approach to normalize blood glucose levels in people with type 2 diabetes. The existing technology was developed by a team of scientists at GE HealthCare’s HealthCare Technology and Innovation Center, formerly part of the GE Research Center.